<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Lenalidomide, a derivative of thalidomide, is an immunomodulatory agent introduced in 2004 for the treatment of <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> in combination with <z:chebi fb="0" ids="41879">dexamethasone</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>It is also indicated for the treatment of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> and is currently under investigative use for metastatic <z:hpo ids='HP_0002861'>melanoma</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>We present a case of <z:e sem="disease" ids="C1142272" disease_type="Disease or Syndrome" abbrv="">neutrophilic dermatosis</z:e> involving predominantly the lower extremities in a patient receiving lenalidomide therapy for <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> </plain></SENT>
</text></document>